Overview

Impact of Proteasome Inhibition on Anti-Donor HLA Antibody Production After Kidney Transplantation

Status:
Terminated
Trial end date:
2015-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to see if treating patients who have high levels of donor specific alloantibodies post-transplant with bortezomib might prevent the development of transplant glomerulopathy and preserve allograft function.
Phase:
Phase 2
Details
Lead Sponsor:
Mark Stegall
Collaborator:
Millennium Pharmaceuticals, Inc.
Treatments:
Antibodies
Bortezomib